The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.
The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The award is one of 121 for projects in New York City this year, totaling $64.8 million.
The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Celmatix's Fertilome test aims to give women genetic insight into their fertility.
The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.
They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.